Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment

Anne Sofie Bjerrum, Skjold Tina, Schmid Johannes Martin
European Respiratory Journal 2021 58: PA3732; DOI: 10.1183/13993003.congress-2021.PA3732
Anne Sofie Bjerrum
1Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Århus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: annbjerr@rm.dk
Skjold Tina
1Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Århus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Schmid Johannes Martin
1Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Århus, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: Clinical trials have shown oral corticosteroid (OCS) sparing effects of anti-IL5/anti-IL5-receptor treatments. The generalisability of these trials may be limited, due to the rigid inclusion and exclusion criteria, and the short tapering duration. Real-life evidence may bridge the gap between the clinical trials and the clinical practice. We present real-life data on the OCS sparing effects of anti-IL5/anti-IL5-receptor treatments after 12 and 24 months of treatment.

Methods: We included severe, eosinophilic asthma patients treated with mepolizumab, reslizumab or benralizumab for 24 months. Data on OCS-dose, FEV1, ACT/ACQ score and blood eosinophils were collected from the patients records before and after 12 and 24 months of anti-IL5/anti-IL5-receptor treatment.

Results: At baseline 75% of patients were on daily OCS. This number was reduced to 50% and 28% after one and two years of treatment, p< 0.001. Within the group on daily OCS the median daily dose was reduced from 10 mg (IQR 5-20) Prednisolone at baseline to 3.75 mg (IQR 0-10) and 0 mg (IQR 0-7.5) Prednisolone after 12 and 24 months, p< 0.001. At baseline 29% of patients scored themselves as being wellcontrolled, increasing to 45% and 52% after one and two years of treatment, respectively.

Conclusions: The findings in this study add to the generalisability of the clinical studies, showing significant OCS sparing effects of anti-IL5/anti-IL5-receptor treatment in a real-life clinical setting. These findings add to the understanding of the long-term effects of anti-IL5/anti-IL5-receptor treatment, showing an even further and persistent OCS sparing effect after two years of treatment, without jeopardizing the asthma control.

  • Treatments
  • Severe asthma
  • Asthma - management

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3732.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment
Anne Sofie Bjerrum, Skjold Tina, Schmid Johannes Martin
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3732; DOI: 10.1183/13993003.congress-2021.PA3732

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment
Anne Sofie Bjerrum, Skjold Tina, Schmid Johannes Martin
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3732; DOI: 10.1183/13993003.congress-2021.PA3732
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Impact of biologic therapy in severe asthma with nasal polyps
  • Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
  • Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society